COVID-19 and Anosmia: Prevalence, Molecular Analysis, Clinical Trial [COVID-19]
Research type
Research Study
Full title
SARS-CoV-2 infection/Covid-19 and anosmia – prevalence study, molecular analysis and clinical trial
IRAS ID
283758
Contact name
Valerie J. Lund
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
The CDC has recently added loss of smell to its list of symptoms related to COVID-19 infection, which has been widely reported as a key symptom at presentation. This topic has received significant press coverage, especially with regard to potential implications, such as the need for self-isolation with these symptoms during the Covid-19 pandemic. We seek to assess the prevalence of anosmia in a sample of UK patients, who were diagnosed with COVID-19 on the basis of swab tests, and are enrolled through the UK Biobank or are affected staff at Barts Health NHS Trust, University College London Hospital or James Paget University Hospitals via staff surveys. We plan to conduct a randomised controlled clinical trial for the evaluation of the efficacy of olfactory training for the treatment of anosmia secondary to COVID-19 infection. We will use a standardized smell test to determine baseline smelling capacity and potential improvements at the end of the study.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
20/WM/0147
Date of REC Opinion
12 May 2020
REC opinion
Further Information Favourable Opinion